MX2016013375A - Tratamiento de la hgna y ehna. - Google Patents

Tratamiento de la hgna y ehna.

Info

Publication number
MX2016013375A
MX2016013375A MX2016013375A MX2016013375A MX2016013375A MX 2016013375 A MX2016013375 A MX 2016013375A MX 2016013375 A MX2016013375 A MX 2016013375A MX 2016013375 A MX2016013375 A MX 2016013375A MX 2016013375 A MX2016013375 A MX 2016013375A
Authority
MX
Mexico
Prior art keywords
nafld
nash
treatment
mbx
therapy
Prior art date
Application number
MX2016013375A
Other languages
English (en)
Other versions
MX369921B (es
Inventor
A Mcwherter Charles
Roberts Brian
Wang Xueyan
Jung Choi Yun-
Karpf David
Martin Robert
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53373532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016013375(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of MX2016013375A publication Critical patent/MX2016013375A/es
Publication of MX369921B publication Critical patent/MX369921B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Abstract

La presente invención se refiere al tratamiento del NAFLD y la NASH por terapia con MBX-8025 o una sal de MBX-8025.
MX2016013375A 2014-04-11 2015-04-10 Tratamiento de la hgna y ehna. MX369921B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461978335P 2014-04-11 2014-04-11
PCT/US2015/025416 WO2015157697A1 (en) 2014-04-11 2015-04-10 Treatment of nafld and nash

Publications (2)

Publication Number Publication Date
MX2016013375A true MX2016013375A (es) 2017-02-15
MX369921B MX369921B (es) 2019-11-26

Family

ID=53373532

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013375A MX369921B (es) 2014-04-11 2015-04-10 Tratamiento de la hgna y ehna.

Country Status (26)

Country Link
US (7) US9381181B2 (es)
EP (1) EP3129018B1 (es)
JP (1) JP6865038B2 (es)
KR (1) KR102374499B1 (es)
CN (1) CN106163508A (es)
AU (1) AU2015243239B2 (es)
BR (1) BR112016023269A8 (es)
CA (1) CA2944139C (es)
CL (1) CL2016002517A1 (es)
CY (1) CY1122602T1 (es)
DK (1) DK3129018T3 (es)
EA (1) EA036704B1 (es)
ES (1) ES2764467T3 (es)
HR (1) HRP20192299T1 (es)
IL (1) IL248193B (es)
LT (1) LT3129018T (es)
MX (1) MX369921B (es)
NZ (1) NZ724740A (es)
PH (1) PH12016501978A1 (es)
PL (1) PL3129018T3 (es)
PT (1) PT3129018T (es)
RS (1) RS59637B1 (es)
SG (1) SG11201608077PA (es)
SI (1) SI3129018T1 (es)
UA (1) UA121208C2 (es)
WO (1) WO2015157697A1 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2334295B1 (en) 2008-09-02 2017-06-28 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
CA2740874C (en) 2008-10-17 2018-02-27 Metabolex, Inc. Use of ppar.gamma.agonists to reduce small dense ldl particles
MX2011011538A (es) 2009-04-29 2012-06-13 Amarin Pharma Inc Composicion farmaceutica estable y metodos de uso de la misma.
NZ771180A (en) 2009-04-29 2022-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
ES2856959T3 (es) 2009-06-15 2021-09-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para el tratamiento del ictus en un sujeto en terapia simultánea con estatina
EP2480248B1 (en) 2009-09-23 2015-09-02 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ727980A (en) 2010-11-29 2018-08-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
RS61557B1 (sr) 2012-06-29 2021-04-29 Amarin Pharmaceuticals Ie Ltd Postupci za smanjenje rizika od kardiovaskularnog događaja kod pacijenta na terapiji statinom primenom etil estra eikozapentaenske kiseline
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) * 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
EP3119384B1 (en) 2014-03-20 2018-09-12 CymaBay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
RS59637B1 (sr) * 2014-04-11 2020-01-31 Cymabay Therapeutics Inc Tretiranje nafld i nash
AU2015267148B2 (en) 2014-05-28 2021-07-29 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
EP3207123A1 (en) 2014-10-17 2017-08-23 Children's Hospital Center D/b/a Cincinnati Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
MX2017012319A (es) * 2015-03-26 2018-05-11 T3D Therapeutics Inc Metodos para tratar enfermedad hepática utilizando derivados de acido indano acético.
BR112017023164A2 (pt) 2015-04-28 2018-07-24 Pronova Biopharma Norge As composto, e, método de prevenir e/ou tratar a esteato-hepatite não alcoólica em um indivíduo em necessidade do mesmo
WO2017049157A1 (en) * 2015-09-18 2017-03-23 Duke University Methods and compositions for the treatment of steatosis-associated disorders
WO2017139708A1 (en) 2016-02-10 2017-08-17 Synlogic, Inc. Bacteria engineered to treat nonalcoholic steatohepatitis (nash)
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
CN109415685B (zh) 2016-05-05 2023-07-04 儿童医院医疗中心 用于体外制造胃底组织的方法和与其相关的组合物
GB201614455D0 (en) * 2016-08-24 2016-10-05 Univ Oxford Innovation Ltd Biomarkers
NZ753051A (en) * 2016-11-04 2023-03-31 Children’S Hospital Medical Center Liver organoid compositions and methods of making and using same
US10493363B2 (en) * 2016-11-09 2019-12-03 Activision Publishing, Inc. Reality-based video game elements
SG10202105768WA (en) 2016-12-05 2021-06-29 Childrens Hospital Med Ct Colonic organoids and methods of making and using same
EP4234536A3 (en) 2017-05-05 2023-10-25 Hepanova, Inc. Amino-aryl-benzamide compounds and methods of use thereof
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US20200276178A1 (en) 2017-09-13 2020-09-03 Novartis Ag Combinations comprising fxr agonists
US11260066B2 (en) 2017-10-27 2022-03-01 Samyang Corporation Inhibiting reduction of lean body mass and inhibiting accumulation of liver fat by administering allulose
IL308604A (en) 2017-12-06 2024-01-01 Basf As Fatty acid antecedents for the treatment of nonalcoholic fatty liver disease
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA51766A (fr) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
EP3880187A1 (en) 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Treatment of obesity and its complications
WO2020102337A1 (en) * 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Combination treatment of nafld and nash
WO2021097027A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of alcoholic liver disease
US20210145775A1 (en) * 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of intestinal barrier dysfunction and associated diseases
JP2023525571A (ja) * 2020-05-13 2023-06-16 ターンズ・ファーマシューティカルズ・インコーポレイテッド 肝障害の併用処置
WO2022238445A1 (en) * 2021-05-11 2022-11-17 Genfit Ppar-agonists for use in the treatment of liver failure

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
JPH10512894A (ja) 1995-03-06 1998-12-08 アイシス・ファーマシューティカルス・インコーポレーテッド ２’−ｏ−置換ピリミジンおよびそのオリゴマー化合物の合成の改良法
CZ243498A3 (cs) 1996-02-14 1999-09-15 Isis Pharmaceuticals, Inc. Oligonukleotidy s mezerou a modifikovaným cukrem
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
EP1667964B1 (en) 2003-09-19 2009-07-22 Janssen Pharmaceutica N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
DK1725234T4 (en) 2004-03-05 2016-05-09 Univ Pennsylvania METHODS OF TREATING DISEASES OR DISEASES CONNECTED WITH HYPERLIPIDEMIA AND HYPERCOLESTEROLYMIA WITH MINIMIZATION OF SIDE EFFECTS
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
WO2008091863A1 (en) 2007-01-23 2008-07-31 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
CA2740874C (en) 2008-10-17 2018-02-27 Metabolex, Inc. Use of ppar.gamma.agonists to reduce small dense ldl particles
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
CA2930069A1 (en) 2013-11-20 2015-05-28 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
EP3119384B1 (en) 2014-03-20 2018-09-12 CymaBay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
RS59637B1 (sr) * 2014-04-11 2020-01-31 Cymabay Therapeutics Inc Tretiranje nafld i nash
MX2016017081A (es) 2014-06-26 2017-05-01 Cymabay Therapeutics Inc Tratamiento de hipertrigliceridemia grave.

Also Published As

Publication number Publication date
BR112016023269A8 (pt) 2021-06-29
CY1122602T1 (el) 2021-03-12
JP2017513836A (ja) 2017-06-01
KR20160136451A (ko) 2016-11-29
CA2944139C (en) 2020-11-03
AU2015243239B2 (en) 2019-11-14
CA2944139A1 (en) 2015-10-15
DK3129018T3 (da) 2020-01-20
CL2016002517A1 (es) 2017-05-05
EP3129018B1 (en) 2019-10-23
US10188620B2 (en) 2019-01-29
SG11201608077PA (en) 2016-10-28
US20150290154A1 (en) 2015-10-15
UA121208C2 (uk) 2020-04-27
US9616039B2 (en) 2017-04-11
IL248193B (en) 2019-03-31
US20180228752A1 (en) 2018-08-16
US10342770B2 (en) 2019-07-09
CN106163508A (zh) 2016-11-23
PH12016501978A1 (en) 2016-12-19
MX369921B (es) 2019-11-26
US20190142776A1 (en) 2019-05-16
US20180008566A1 (en) 2018-01-11
PT3129018T (pt) 2020-01-15
US9962346B2 (en) 2018-05-08
EP3129018A1 (en) 2017-02-15
PL3129018T3 (pl) 2020-05-18
WO2015157697A1 (en) 2015-10-15
US11179359B2 (en) 2021-11-23
LT3129018T (lt) 2020-01-10
NZ724740A (en) 2019-11-29
ES2764467T3 (es) 2020-06-03
US10722483B2 (en) 2020-07-28
EA201692050A1 (ru) 2017-01-30
US20210038546A1 (en) 2021-02-11
EA036704B1 (ru) 2020-12-10
HRP20192299T1 (hr) 2020-03-06
AU2015243239A1 (en) 2016-10-20
KR102374499B1 (ko) 2022-03-14
US20160324812A1 (en) 2016-11-10
US9381181B2 (en) 2016-07-05
BR112016023269A2 (pt) 2017-08-15
SI3129018T1 (sl) 2020-02-28
RS59637B1 (sr) 2020-01-31
JP6865038B2 (ja) 2021-04-28
US20200009092A1 (en) 2020-01-09

Similar Documents

Publication Publication Date Title
PH12016501978A1 (en) Treatment of nafld and nash
IL283258A (en) A preparation for the treatment of hypothyroidism
NZ731467A (en) Anti-tim3 antibodies and methods of use
HRP20190580T1 (hr) Kombinirana terapija radi liječenja rezistentnih bakterijskih infekcija
IL261959A (en) Cancer treatment with tg02
IL251761A0 (en) Cancer treatment with immune system stimulants
PH12016501769B1 (en) Treatment of intrahepatic cholestatic diseases
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
HK1249866A1 (zh) 用他塞利昔布進行治療的方法
MX2016012244A (es) Compuestos y sus metodos de uso.
RS61481B1 (sr) Lečenje migrene acetil-leucinom
EA201691907A1 (ru) Комбинированная терапия кураксинами

Legal Events

Date Code Title Description
FG Grant or registration